Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients

Abstract Introduction RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time to discontinuation of initial RA treatment along with patient baseline characteristics. This study’s primary objective was to assess the time...

Full description

Bibliographic Details
Main Authors: Rieke Alten, Gerd R. Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör, Khai Jing Ng, Jens Gerwien, Liliana Zaremba-Pechmann, Alan J. M. Brnabic, Bruno Fautrel
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-09-01
Series:Rheumatology and Therapy
Subjects:
Baricitinib
Comparative effectiveness
Real-world evidence
Rheumatoid arthritis
Treatment discontinuation
Online Access:https://doi.org/10.1007/s40744-023-00597-3

Internet

https://doi.org/10.1007/s40744-023-00597-3

Similar Items